Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant dose-ranging study in allergic asthma
NCT01437735Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 2 trial of fevipiprant in allergic asthma, sponsored by Novartis. Started Aug 2011; status: completed.
02
Drugs
fevipiprant
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01437735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01437735.